Amoxil (amoxicillin) SPC and PIL updates
Please note that the Amoxil SPCs and PILs were updated on 21st April 2016 in line with European Harmonisation Process. Please see the Amoxil product page for further information.
View our products
Find comprehensive information on our products including resources for patients.
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, email@example.com. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Amoxil, Relvar and Ellipta are registered trademarks of the GSK group of companies.